ADXS11-001 LM-LLO as specific immunotherapy in cervical cancer

References

• International Agency for Research on Cancer. Mexico source: globocan 2018. Glob Cancer Obs 2019;283:2018–19.
   Google Scholar
• Wang R, Pan W, Jin L, Huang W, Li Y, Wu D, Gao C, Ma D, Liao S. Human papillomavirus vaccine against cervical cancer: opportunity and challenge. Cancer Lett. 2020;471:88–102. doi:10.1016/j.canlet.2019.11.039.
   PubMed Web of Science ®Google Scholar
• Eskander RN, Tewari KS. Immunotherapy : an evolving paradigm in the treatment of advanced cervical cancer. Clin Ther. 2015;37(1):20–38. doi:10.1016/j.clinthera.2014.11.010.
   PubMed Web of Science ®Google Scholar
• Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology. 2007;121:1–14. doi:10.1111/j.1365-2567.2007.02587.x.
   PubMed Web of Science ®Google Scholar
• Lauer P, Chow MY, Loessner MJ, Portnoy DA, Calendar R. Construction, characterization, and use of two listeria monocytogenes site-specific phage integration vectors. J Bacterology. 2002;184(15):4177–86. doi:10.1128/JB.184.15.4177-4186.2002.
   PubMed Web of Science ®Google Scholar
• Le DT, Dubensky TW Jr, Brockstedt DG. Clinical development of listeria monocytogenes–based immunotherapies. Semin Oncol. 2012;39(3):311–22. doi:10.1053/j.seminoncol.2012.02.008.
   PubMed Web of Science ®Google Scholar
• Wallecha A, French C, Petit R, Singh R, Amin A, Rothman J. Lm-LLO-based immunotherapies and HPV-associated disease. J Oncol. 2012;2012:542851. doi:10.1155/2012/542851.
   PubMedGoogle Scholar
• Shahabi V, Reyes-Reyes M, Wallecha A, Rivera S, Paterson Y, MacIag P. Development of a Listeria monocytogenes based vaccine against prostate cancer. Cancer Immunol Immunother. 2008;57(9):1301–13. doi:10.1007/s00262-008-0463-z.
   PubMed Web of Science ®Google Scholar
• Wallecha A, Wood L, Pan ZK, Maciag PC, Shahabi V, Paterson Y. Listeria monocytogenes-derived listeriolysin O has pathogen-associated molecular pattern-like properties independent of its hemolytic ability. Clin Vaccine Immunol. 2013;20(1):77–84. doi:10.1128/CVI.00488-12.
   PubMed Web of Science ®Google Scholar
• Miles BA, Monk BJ, Safran HP. Mechanistic insights into ADXS11-001 human papillomavirus-associated cancer immunotherapy. Gynecol Oncol Res Pract. 2017;4(1):9. doi:10.1186/s40661-017-0046-9.
   PubMedGoogle Scholar
• Plummer M, De Martel C, Vignat J, Ferlay J, Bray F, Franceschi S. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Heal. 2016;4(9):e609–16. doi:10.1016/S2214-109X(16)30143-7.
   PubMed Web of Science ®Google Scholar
• Galani E, Christodoulou C. Human papilloma viruses and cancer in the post-vaccine era. Clin Microbiol Infect. 2009;15(11):977–81. doi:10.1111/j.1469-0691.2009.03032.x.
   PubMed Web of Science ®Google Scholar
• Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2(5):342–50. doi:10.1038/nrc798.
   PubMed Web of Science ®Google Scholar
• Bodily J, Laimins LA. Persistence of human papillomavirus infections: keys to malignant progression. Trends Microbiol. 2012;19(1):33–39. doi:10.1016/j.tim.2010.10.002.
   Web of Science ®Google Scholar
• Øvestad IT, Gudlaugsson E, Skaland I, Malpica A, Kruse AJ, Janssen EAM, Baak JPA. Local immune response in the microenvironment of CIN2-3 with and without spontaneous regression. Mod Pathol. 2010;23(9):1231–40. doi:10.1038/modpathol.2010.109.
   PubMed Web of Science ®Google Scholar
• Patel S, Chiplunkar S. Host immune responses to cervical cancer. Curr Opin Obstet Gynecol. 2009;21(1):54–59. doi:10.1097/GCO.0b013e32831a9890.
   PubMed Web of Science ®Google Scholar
• Renier S, Hébraud M, Desvaux M. Molecular biology of surface colonization by Listeria monocytogenes: an additional facet of an opportunistic Gram-positive foodborne pathogen. Environ Microbiol. 2011;13(4):835–50. doi:10.1111/j.1462-2920.2010.02378.x.
   PubMed Web of Science ®Google Scholar
• Pamer EG. Inmune Responses to Listeria Monocytogenes. Nat Rev. 2004;4:812–23.
   Google Scholar
• Reniere ML, Whiteley AT, Portnoy DA. An In Vivo Selection Identifies Listeria monocytogenes genes required to sense the intracellular environment and activate virulence factor expression. PLOS Pathog. 2016 Jul 14;12(7):e1005741. doi:10.1371/journal.ppat.1005741.
   PubMed Web of Science ®Google Scholar
• Flickinger JC Jr, Rodeck U, Snook AE. Listeria monocytogenes as a vector for cancer immunotherapy : current understanding and progress. vaccines. 2018;6(3):48. doi:10.3390/vaccines6030048.
   PubMed Web of Science ®Google Scholar
• Rothman J, Paterson Y. Live-attenuated Listeria -based immunotherapy. Expert Rev Vaccines. 2013;12(5):493–504. doi:10.1586/erv.13.34.
   PubMed Web of Science ®Google Scholar
• Zenewicz LA, Shen H. Innate and adaptive immune responses to Listeria monocytogenes : a short overview. Microbes Infect. 2007;9:1208–15. doi:10.1016/j.micinf.2007.05.008.
   PubMed Web of Science ®Google Scholar
• Cory L, Chu C. ADXS-HPV: a therapeutic Listeria vaccination targeting cervical cancers expressing the HPV E7 antigen. Hum Vaccin Immunother. 2014;10(11):3190–95. doi:10.4161/hv.34378.
   PubMed Web of Science ®Google Scholar
• Gunn GR, Zubair A, Peters C, Pan ZK, Wu TC, Paterson Y. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J Immunol. 2001;167:6471–79. doi:10.4049/jimmunol.167.11.6471.
   PubMed Web of Science ®Google Scholar
• Sewell DA, Shahabi V, Gun G 3rd, Pan ZK, Dominiecki ME, Paterson Y. Recombinant Listeria Vaccines containing PEST sequences are potent immune adjuvants for the tumor-associated antigen human papillomavirus-16 E7. Cancer Res. 2004;64:8821–25. doi:10.1158/0008-5472.CAN-04-1958.
   PubMed Web of Science ®Google Scholar
• Peng X, Hussain SF, Paterson Y, Alerts E. The ability of two Listeria monocytogenes vaccines targeting human papillomavirus-16 E7 to induce an antitumor response correlates with myeloid dendritic cell function. J Immunol. 2004;172:6030–38. doi:10.4049/jimmunol.172.10.6030.
   PubMed Web of Science ®Google Scholar
• Peng X, Treml J, Paterson Y. Adjuvant properties of listeriolysin O protein in a DNA vaccination strategy. Cancer Immunol Immunother. 2014;56(6):797–806. doi:10.1007/s00262-006-0240-9.
   Google Scholar
• Lamikanra A, Pan ZK, Isaacs SN, Wu T, Paterson Y. Regression of established human papillomavirus type 16 (hpv-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8 (+) T-cell responses that home to the tumor site. J Virol. 2001;75(20):9654–64. doi:10.1128/JVI.75.20.9654-9664.2001.
   PubMed Web of Science ®Google Scholar
• Sun R, Liu Y. Listeriolysin O as a strong immunogenic molecule for the development of new anti-tumor vaccines. Hum Vaccin Immunother. 2013;9(5):1058–68. doi:10.4161/hv.23871.
   PubMed Web of Science ®Google Scholar
• Freeman MM, Ziegler HK. Simultaneous Th1-type cytokine expression is a signature of peritoneal CD4 + lymphocytes responding to infection with Listeria monocytogenes. J Immunol. 2005;175:394–403. doi:10.4049/jimmunol.175.1.394.
   PubMed Web of Science ®Google Scholar
• Maciag PC, Radulovic S, Rothman J. The first clinical use of a live-attenuated Listeria monocytogenes vaccine : a Phase I safety study of Lm -LLO-E7 in patients with advanced carcinoma of the cervix. Vaccine. 2009;27:3975–83. doi:10.1016/j.vaccine.2009.04.041.
   PubMed Web of Science ®Google Scholar
• Ghamande SA, Platt D, Wheatley D, Rungruang BJ. Phase I study evaluating high-dose treatment with ADXS11-001, a Listeria monocytogenes - listeriolysin O (Lm -LLO) immunotherapy, in women with cervical cancer. J Clin Oncol. 2015;33(suppl):abstractTPS3096. doi:10.1200/jco.2015.33.15_suppl.tps3096.
   Google Scholar
• Huh WK, Brady WE, Moore KN, Lankes HA, Bradley J. A phase 2 study of live-attenuated listeria monocytogenes cancer immunotherapy (ADXS11-001) in the treatment of persistent or recurrent cancer of the cervix (GOG-0265). J Clin Oncol. 2014;32(suppl):abstractTPS5617. doi:10.1200/jco.2014.32.15_suppl.tps5617.
   Google Scholar
• Basu P, Mehta A, Jain M, Gupta S, Nagarkar RV, John S, Petit R. A randomized phase 2 study of ADXS11-001 Listeria monocytogenes Y Listeriolysin O immunotherapy with or without cisplatin in treatment of advanced cervical cancer. Int J Gynecol Cancer. 2018;28(4):764–72. doi:10.1097/IGC.0000000000001235.
   PubMed Web of Science ®Google Scholar
• Miles B, Safran HP, Monk BJ. Therapeutic options for treatment of human papillomavirus-associated cancers - novel immunologic vaccines: ADXS11–001. Gynecol Oncol Res Pract. 2017;4(1):10. doi:10.1186/s40661-017-0047-8.
   PubMedGoogle Scholar
• Herzog T, Backes FJ, Copeland L, Del M, Estevez P, Hare TW, Huh W, Kim B, Moore K, Oaknin A, et al. AIM2CERV: a randomized phase 3 study of adjuvant AXAL immunotherapy following chemoradiation in patients who have high-risk locally advanced cervical cancer (HRLACC). Immunother Cancer. 2016;4(suppl):abstractP140.
   Google Scholar
• Cohen EEW, Moore KN, Slomovitz BM, Chung CH, Anderson ML, Morris SR, Mauro D, Burtness B. Phase I/II study of ADXS11-001 or MEDI4736 immunotherapies alone and in combination, in patients with recurrent/metastatic cervical or human papillomavirus (HPV) -positive head and neck cancer. J Immunother Cancer. 2015;3(Suppl2):abstractP147. doi:10.1186/2051-1426-3-S2-P147.
   Google Scholar
• Krupar R, Imai N, Miles B, Genden E, Misiukiewicz K, Saenger Y, Demicco E, Patel J, Herrera PC, Parikh F, et al. HPV E7 antigen-expressing Listeria-based immunotherapy (ADXS11-001) prior to robotic surgery for HPV-positive oropharyngeal cancer enhances HPV- specific T cell immunity. Cancer Res. 2016;76(14suppl):abstract LB–095.
   Google Scholar
• Safran H, Leonard K, Perez K, Vrees M, Klipfel A, Schechter S, Oldenburg N, Roth L, Shah N, Rosati K, et al. Tolerability of ADXS11-001 Lm -LLO Listeria-based immunotherapy with mitomycin, fluorouracil, and radiation for anal cancer. Int J Radiat Oncol Biol Phys. 2019;100(5):1175–78. doi:10.1016/j.ijrobp.2018.01.004.
   Web of Science ®Google Scholar
• Fakih M, Neil BHO, Chiorean EG, Hochster HS, Mauro DJ, More S. Phase II study of ADXS11-001 in patients with persistent/recurrent, locoregional or metastatic squamous cell carcinoma of the anorectal canal. J Clin Oncol. 2016;34(4suppl):abstractTPS786. doi:10.1200/jco.2016.34.4_suppl.tps786.
   Google Scholar
• Sacco JJ, Evans M, Harrington KJ, Man S, Powell N, Shaw RJ, Jones TM. Systemic listeriosis following vaccination with the attenuated Listeria monocytogenes therapeutic vaccine, ADXS11-001. Hum Vaccin Immunother. 2016;12(4):1085–86. doi:10.1080/21645515.2015.1121338.
   PubMed Web of Science ®Google Scholar
• Castro-Eguiluz D, Barquet-Muñoz SA, Arteaga-Gómez AC, Salcedo Hernández RA, Rodríguez-Trejo A, Gallardo-Rincón D, Serrano-Olvera JA, Aranda-Flores C. Therapeutic use of human papillomavirus vaccines in cervical lesions. Rev Invest Clin. 2020;72(4):239–49. doi:10.24875/RIC.20000059.
   PubMedGoogle Scholar
• Grabowska AK, Kaufmann AM, Riemer AB. Identification of promiscuous HPV16-derived T helper cell epitopes for therapeutic HPV vaccine design. Int J Cancer. 2015;136:212–24. doi:10.1002/ijc.28968.
   PubMed Web of Science ®Google Scholar
• Yang A, Farmer E, Wu TC, Hung CF. Perspectives for therapeutic HPV vaccine development. J Biomed Sci. 2016;23:75. doi:10.1186/s12929-016-0293-9.
   PubMed Web of Science ®Google Scholar
• Trimble CL, Morrow MP, Kraynyak KA, Shen X, Dallas M, Yan J, Edwards L, Parker RL, Denny L, Giffear M, et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet. 2015;386(10008):2078–88. doi:10.1016/S0140-6736(15)00239-1.
   PubMed Web of Science ®Google Scholar
• De Vos Van Steenwijk PJ, Ramwadhdoebe TH, Löwik MJG, Van Der Minne CE, Berends-van Der Meer DMA, Fathers LM, Valentijn ARPM, Oostendorp J, Fleuren GJ, Hellebrekers BWJ, et al. A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions. Cancer Immunol Immunother. 2012;61(9):1485–92. doi:10.1007/s00262-012-1292-7.
   PubMed Web of Science ®Google Scholar
• Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, García P, et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res. 2009;2(10):868–78. doi:10.1158/1940-6207.CAPR-09-0031.
   PubMed Web of Science ®Google Scholar
• Thiers BH. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. Yearb Dermatology Dermatologic Surg. 2011;2008:148–49. doi:10.1016/S0093-3619(08)70789-5.
   Google Scholar
• Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, Schiller JT, Gonzalez P, Dubin G, Porras C, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. J Am Med Assoc. 2007;298(7):743–53. doi:10.1001/jama.298.7.743.
   PubMed Web of Science ®Google Scholar
• Arbyn M, Xu L, Simoens C, Martin-Hirsch PPL. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. 2018;(5):Art. No.: CD009069. doi:10.1002/14651858.CD009069.pub.
   Google Scholar